'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: Systematic review

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 5, 2016, Pages 593-610

  Abraham, I ^a,b,c   Alhossan, A ^a,d   Lee, C S ^e   Kutbi, H ^a,f   MacDonald, K ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c Matrix45   (United States)

^d KING SAUD UNIVERSITY   (Saudi Arabia)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

allergic asthma; effectiveness; IgE; omalizumab; systematic review

Indexed keywords

ANTIASTHMATIC AGENT; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OMALIZUMAB; THEOPHYLLINE DERIVATIVE; IMMUNOGLOBULIN E;

ALLERGIC ASTHMA; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DRUG EFFICACY; EMERGENCY CARE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEVERE ALLERGIC ASTHMA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADULT; ASTHMA; CLINICAL STUDY; HEALTH CARE PLANNING; IMMUNOLOGY; META ANALYSIS; METHODOLOGY; PATIENT ATTITUDE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; CLINICAL STUDIES AS TOPIC; HEALTH RESOURCES; HUMANS; IMMUNOGLOBULIN E; OMALIZUMAB; PATIENT ACCEPTANCE OF HEALTH CARE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84959420164     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12815     Document Type: Review

References (54)

1. Martinez FD, Vercelli D,. Asthma. Lancet 2013; 382: 1360-1372.
2. Braman S,. The global burden of asthma. Chest 2006; 1309: 4S-12S.
3. Rabe K, Adachi M, Lai C, Soriano JB, Vermeire PA, Weiss KB, et al., Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 2004; 114: 40-47.
4. Van Ganse E, Laforest L, Pietri G, Boissel JP, Gormand F, Ben-Joseph R, et al., Peristent asthma: disease control, resource utilization and direct costs. Eur Respir J 2002; 20: 260-267.
5. Barnes P, Jonsson B, Klim J,. The costs of asthma. Eur Respir J 1996; 9: 636-642.
6. Bateman E, Hurd S, Barnes P, Bousquet J, Drazen JM, FitzGerald M, et al., Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-178.
7. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al., Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007; 120: 1360-1367.
8. De Marco R, Cazzoletti L, Cerveri I, Corsico A, Bugiani M, Accordini S, et al., Are the asthma guideline goals achieved in daily practice? A population-based study on treatment adequacy and the control of asthma. Int Arch Allergy Immunol 2005; 138: 225-234.
9. Bateman E, Boushey H, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al., Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170: 836-844.
10. Partridge M, Van der Molen T, Myrseth S, Busse W,. Attitudes and action of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6: 13.
11. Gould H, Sutton B, Beavil A, Beavil RL, McCloskey N, Coker HA, et al., The biology of IGE and the basis of allergic disease. Annu Rev Immunol 2003; 21: 579-628.
12. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, et al., Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005; 60: 309-316.
13. Soler M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al., The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-261.
14. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H,. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125: 1378-1386.
15. Buhl R, Hanf G, Soler M, Bensch G, Wolfe J, Everhard F, et al., The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002; 20: 1088-1094.
16. D'Amato G, Bucchioni E, Oldani V, Canonica W,. Treating moderate-to-severe allergic asthma with a recombinant humanized anti-IgE monoclonal antibody (omalizumab). Treat Respir Med 2006; 5: 392-398.
17. D'Amato G, Perticone M, Bucchioni E, Salzillo A, D'Amato M, Liccardi G,. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update. Eur Ann Allergy Clin Immunol 2010; 42: 135-140.
18. Holgate S, Buhl R, Bousquet J, Smith N, Panahloo Z, Jimenez P,. The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009; 103: 1098-1113.
19. Kuhl K, Hanania N,. Targeting IgE in asthma. Curr Opin Pulm Med 2012; 18: 1-5.
20. Pelaia G, Gallelli L, Renda T, Romeo P, Busceti MT, Grembiale RD, et al., Update on optimal use of omalizumab in management of asthma. J Asthma Allergy 2011; 4: 49-59.
21. Menzies-Gow A, Fan Chung K,. Omalizumab for the treatment of severe allergic asthma. Expert Rev Clin Immunol 2008; 4: 543-548.
22. Babu K, Arshad S, Holgate S,. Omalizumab, a novel anti-IgE therapy in allergic disorders. Expert Opin Biol Ther 2001; 1: 1049-1058.
23. Ledford D,. Omalizumab: overview of pharmacology and efficacy in asthma. Expert Opin Biol Ther 2009; 9: 933-943.
24. Corren J, Casala T, Lanier B, Buhl R, Holgate S, Jimenez P,. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39: 788-797.
25. Tan R, Corren J,. Safety of omalizumab in asthma. Expert Opin Drug Saf 2011; 10: 463-471.
26. Rodrigo G, Neffen H, Castro-Rodriguez J,. Efficacy and safety of subcutaneous omalizumab vs. placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35.
27. ®) in the first patients treated in real-life practice in France. Respir Med 2008; 102: 71-76.
28. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, et al., "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009; 103: 1633-1642.
29. Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R,. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009; 103: 1725-1731.
30. Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, et al., Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010; 104: 1381-1385.
31. Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, et al., Italian real-life experience of omalizumab. Respir Med 2010; 104: 1410-1416.
32. Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ,. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011; 180: 637-641.
33. Rottem M,. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma 2012; 49: 78-82.
34. Tzortzaki E, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, et al., Long-term omalizumab treatment in severe allergic asthma: the south-eastern Mediterranean "real-life" experience. Pulm Pharmacol Ther 2012; 25: 77-82.
35. Vennera M, Pérez-de-Llano L, Bardagí S, Ausin P, Sanjuas C, González H, et al., Omalizumab therapy in severe asthma: experience from the Spanish registry-some new approaches. J Asthma 2012; 49: 416-422.
36. Sweeney J, Brightling C, Menzies-Gow A, Niven R, Patterson CC, Heaney LG,. Clinical management and outcomes of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry. Thorax 2012; 67: 754-756.
37. Schumann C, Kropf C, Wibmer T, Rüdiger S, Stoiber KM, Thielen A, et al., Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012; 6: 215-227.
38. Grimaldi-Bensouda L, Zureik M, Aubier M, Humbert M, Levy J, Benichou J, et al., Does omalizumab make a difference to the real-life treatment of asthma exacerbations? Results from a large cohort of patients with severe uncontrolled asthma. Chest 2013; 143: 398-405.
39. Barnes N, Menzies-Gow A, Mansur A, Spencer D, Percival F, Radwan A, et al., Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real-world study. J Asthma 2013; 50: 529-536.
40. Braunstahl G, Chlumský J, Peachey G, Chen CW,. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol 2013; 9: 47.
41. Korn S, Schumann C, Kropf C, Stoiber K, Thielen A, Taube C, et al., Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010; 105: 313-319.
42. Bousquet J, Siergiejko Z, Wiebocka E, Humbert M, Rabe KF, Smith N, et al., Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011; 66: 671-678.
43. Rubin S, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, et al., Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX). J Asthma 2012; 49: 288-293.
44. Vieira T, Oliveira J, Castel-Branco M,. Short and long-term quality of life and asthma control with omalizumab therapy in a real life setting in Portugal. Allergol Immunopathol 2014; 42: 3-10.
45. Alfarroba S, Videira W, Galvão-Lucas C, Carvalho F, Bárbara C,. Clinical experience with Omalizumab in a Portuguese severe asthma unit. Rev Port Pneumol 2014; 20: 78-83.
46. Kelmenson D, Kelly V, Winkler T, Kone MT, Musch G, Melo MF, et al., The effect of omalizumab on ventilation and perfusion in adults with allergic asthma. Am J Nucl Med Mol Imaging 2013; 3: 350-360.
47. Subramaniam A, Al-Alawi M, Hamad S, O'Callaghan J, Lane SJ,. A study into efficacy of omalizumab therapy in patients with severe persistent allergic asthma at a tertiary referral center for asthma in Ireland. QJM 2013; 106: 631-634.
48. Tiro J, Contreras E, Pozo M, Gómez Vera J, Larenas Linnemann D,. Real life study of three years omalizumab in patients with difficult-to-control asthma. Allergol Immunopathol 2015; 43: 120-126.
49. Novelli F, Latorre M, Vergura L, Caiaffa MF, Camiciottoli G, Guarnieri G, et al., Asthma control in severe asthmatics under treatment with omalizumab: a cross-sectional observational study in Italy. Pulm Pharmacol Ther 2015; 31: 123-129.
50. Tajiri T, Niimi A, Matsumoto H, Ito I, Oguma T, Otsuka K, et al., Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study. Ann Allergy Asthma Immunol 2014; 113: 470-475.
51. Rosner B,. Fundamentals of Biostatistics. 7th edn. Boston, MA, USA: Duxbury; 2010.
52. Janson S, Solari P, Trzaskoma B, Chen H, Haselkorn T, Zazzali J,. Omalizumab adherence in an observational study of patients with moderate to severe allergic asthma. Ann Allergy Asthma Immunol 2015; 114: 516-521.
53. Broder MS, Chang EY, Ory C, Kamath T, Sapra S,. Adherence and persistence with omalizumab and fluticasone/salmeterol within a managed care population. Allergy Asthma Proc 2009; 30: 148-157.
54. Zazzali JL, Raimundo KP, Trzaskoma B, Rosén KE, Schatz M,. Changes in asthma control, work productivity, and impairment with omalizumab: 5-year EXCELS study results. Allergy Asthma Proc 2015; 36: 283-292.